VolitionRx Limited (VNRX) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
32/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseVNRX / S&P -66.25% / 15.20% |
WinVNRX / S&P 86.32% / 15.00% |
LoseVNRX / S&P VNRX unavailable / 50.40% |
| 2026-Q11/3 |
LoseVNRX / S&P -23.08% / -4.33% |
WinVNRX / S&P 88.49% / 11.30% |
LoseVNRX / S&P VNRX unavailable / 27.70% |
| 2025-Q41/3 |
LoseVNRX / S&P -61.76% / 2.65% |
WinVNRX / S&P 40.04% / 9.00% |
LoseVNRX / S&P VNRX unavailable / 13.40% |
| 2025-Q31/3 |
LoseVNRX / S&P -10.53% / 8.12% |
WinVNRX / S&P 14.48% / 4.61% |
LoseVNRX / S&P VNRX unavailable / 13.45% |
| 2025-Q22/3 |
WinVNRX / S&P 33.33% / 10.94% |
WinVNRX / S&P 35.10% / 4.83% |
LoseVNRX / S&P VNRX unavailable / 10.63% |
| 2025-Q11/3 |
LoseVNRX / S&P -5.00% / -4.27% |
WinVNRX / S&P 64.15% / 4.98% |
LoseVNRX / S&P VNRX unavailable / 10.57% |
| 2024-Q41/3 |
LoseVNRX / S&P 0.00% / 2.41% |
WinVNRX / S&P 59.10% / 5.25% |
LoseVNRX / S&P VNRX unavailable / 6.15% |
| 2024-Q31/3 |
LoseVNRX / S&P -1.64% / 5.89% |
WinVNRX / S&P 97.50% / 5.89% |
LoseVNRX / S&P VNRX unavailable / 6.11% |
| 2024-Q21/3 |
LoseVNRX / S&P -19.74% / 4.28% |
WinVNRX / S&P 88.32% / 5.38% |
LoseVNRX / S&P VNRX unavailable / 5.12% |
| 2024-Q11/3 |
LoseVNRX / S&P 5.56% / 10.56% |
WinVNRX / S&P 133.06% / 5.71% |
LoseVNRX / S&P VNRX unavailable / 5.59% |
| 2023-Q41/3 |
LoseVNRX / S&P 4.35% / 11.69% |
WinVNRX / S&P 153.04% / 6.81% |
LoseVNRX / S&P VNRX unavailable / 7.78% |
| 2023-Q31/3 |
LoseVNRX / S&P -50.36% / -3.27% |
WinVNRX / S&P 224.04% / 7.52% |
LoseVNRX / S&P VNRX unavailable / -5.03% |
| 2023-Q21/3 |
LoseVNRX / S&P -27.23% / 8.74% |
WinVNRX / S&P 167.73% / 9.50% |
LoseVNRX / S&P VNRX unavailable / -8.57% |
| 2023-Q11/3 |
LoseVNRX / S&P -21.40% / 7.50% |
WinVNRX / S&P 91.36% / 10.77% |
LoseVNRX / S&P VNRX unavailable / -15.69% |
| 2022-Q42/3 |
WinVNRX / S&P 78.68% / 7.56% |
WinVNRX / S&P 240.30% / 11.88% |
LoseVNRX / S&P VNRX unavailable / -17.99% |
| 2022-Q31/3 |
LoseVNRX / S&P -33.66% / -4.88% |
WinVNRX / S&P 142.32% / 13.47% |
LoseVNRX / S&P VNRX unavailable / -1.41% |
| 2022-Q21/3 |
LoseVNRX / S&P -31.89% / -16.10% |
WinVNRX / S&P 233.90% / 13.71% |
LoseVNRX / S&P VNRX unavailable / 11.04% |
| 2022-Q12/3 |
WinVNRX / S&P -4.14% / -4.60% |
WinVNRX / S&P 365.18% / 15.97% |
LoseVNRX / S&P VNRX unavailable / 42.23% |
| 2021-Q41/3 |
LoseVNRX / S&P 1.29% / 11.03% |
WinVNRX / S&P 570.25% / 15.00% |
LoseVNRX / S&P VNRX unavailable / 96.40% |
| 2021-Q31/3 |
LoseVNRX / S&P -5.78% / 0.58% |
WinVNRX / S&P 1213.40% / 10.77% |
LoseVNRX / S&P VNRX unavailable / 69.42% |
| 2021-Q21/3 |
LoseVNRX / S&P -12.96% / 8.55% |
WinVNRX / S&P 154.04% / 6.58% |
LoseVNRX / S&P VNRX unavailable / 51.81% |
| 2021-Q11/3 |
LoseVNRX / S&P -2.83% / 6.17% |
WinVNRX / S&P 117.79% / -1.06% |
LoseVNRX / S&P VNRX unavailable / 7.39% |
| 2020-Q41/3 |
WinVNRX / S&P 21.18% / 12.15% |
LoseVNRX / S&P VNRX unavailable / -3.72% |
LoseVNRX / S&P VNRX unavailable / -33.42% |
| 2020-Q30/3 |
LoseVNRX / S&P -17.48% / 8.93% |
LoseVNRX / S&P VNRX unavailable / -2.04% |
LoseVNRX / S&P VNRX unavailable / -27.10% |
| 2020-Q21/3 |
WinVNRX / S&P 25.08% / 20.54% |
LoseVNRX / S&P VNRX unavailable / -0.46% |
LoseVNRX / S&P VNRX unavailable / -27.11% |
| 2020-Q10/3 |
LoseVNRX / S&P -34.39% / -19.60% |
LoseVNRX / S&P VNRX unavailable / 3.47% |
LoseVNRX / S&P VNRX unavailable / -14.75% |
| 2019-Q40/3 |
LoseVNRX / S&P -15.66% / 9.07% |
LoseVNRX / S&P VNRX unavailable / 5.36% |
LoseVNRX / S&P VNRX unavailable / 2.99% |
| 2019-Q31/3 |
WinVNRX / S&P 78.98% / 1.70% |
LoseVNRX / S&P VNRX unavailable / 5.02% |
LoseVNRX / S&P VNRX unavailable / 0.21% |
| 2019-Q20/3 |
LoseVNRX / S&P -3.38% / 4.30% |
LoseVNRX / S&P VNRX unavailable / 6.64% |
LoseVNRX / S&P VNRX unavailable / 8.65% |
| 2019-Q11/3 |
WinVNRX / S&P 79.56% / 13.65% |
LoseVNRX / S&P VNRX unavailable / 8.12% |
LoseVNRX / S&P VNRX unavailable / 14.29% |
| 2018-Q40/3 |
LoseVNRX / S&P -30.12% / -13.52% |
LoseVNRX / S&P VNRX unavailable / 9.05% |
LoseVNRX / S&P VNRX unavailable / 18.23% |
| 2018-Q31/3 |
WinVNRX / S&P 29.50% / 7.71% |
LoseVNRX / S&P VNRX unavailable / 10.21% |
LoseVNRX / S&P VNRX unavailable / 19.06% |
| 2018-Q20/3 |
LoseVNRX / S&P -16.67% / 3.43% |
LoseVNRX / S&P VNRX unavailable / 9.03% |
LoseVNRX / S&P VNRX unavailable / 14.46% |
| 2018-Q10/3 |
LoseVNRX / S&P -18.37% / -0.76% |
LoseVNRX / S&P VNRX unavailable / 7.68% |
LoseVNRX / S&P VNRX unavailable / 12.46% |
| 2017-Q41/3 |
WinVNRX / S&P 11.79% / 6.64% |
LoseVNRX / S&P VNRX unavailable / 7.03% |
LoseVNRX / S&P VNRX unavailable / 13.82% |
| 2017-Q30/3 |
LoseVNRX / S&P -25.71% / 4.48% |
LoseVNRX / S&P VNRX unavailable / 5.68% |
LoseVNRX / S&P VNRX unavailable / 17.57% |
| 2017-Q20/3 |
LoseVNRX / S&P -11.94% / 3.09% |
LoseVNRX / S&P VNRX unavailable / 4.83% |
LoseVNRX / S&P VNRX unavailable / 17.74% |
| 2017-Q10/3 |
LoseVNRX / S&P -12.04% / 6.07% |
LoseVNRX / S&P VNRX unavailable / 3.67% |
LoseVNRX / S&P VNRX unavailable / 13.32% |
| 2016-Q40/3 |
LoseVNRX / S&P -13.77% / 3.82% |
LoseVNRX / S&P VNRX unavailable / 2.09% |
LoseVNRX / S&P VNRX unavailable / 7.05% |
| 2016-Q31/3 |
WinVNRX / S&P 68.25% / 3.85% |
LoseVNRX / S&P VNRX unavailable / 0.20% |
LoseVNRX / S&P VNRX unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | VNRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.38% | 20.78% |
| Annualized return | -96.38% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | VNRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.25% | 83.14% |
| Annualized return | -62.41% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | VNRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.30% | 319.30% |
| Annualized return | -39.13% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |